Related Experiment Video
Updated: Sep 10, 2025

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
GlycoRNAs as emerging drug targets.
Bingzhi Li1, Xiaolong Zheng2, Xing Zhang1
1State Key Laboratory of Microbial Technology, Nanjing Normal University, Nanjing 211166, China; School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing 211166, China.
Glycosylated noncoding RNAs (GlycoRNAs) on cell surfaces are key in cell communication. This review explores their role in diseases like cancer and inflammation and discusses therapeutic strategies.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- Glycosylated noncoding RNAs (GlycoRNAs) are emerging as critical molecules on the cell surface.
- They play significant roles in intercellular communication.
- Dysregulation of GlycoRNAs is implicated in various diseases, including inflammation and cancer.
Purpose of the Study:
- To review current understanding of GlycoRNAs in disease.
- To summarize therapeutic strategies targeting GlycoRNAs.
- To outline challenges in developing GlycoRNA-based interventions.
Main Methods:
- Literature review of recent studies on GlycoRNAs.
- Analysis of GlycoRNA involvement in inflammatory and cancerous conditions.
- Evaluation of existing and proposed therapeutic approaches.
Main Results:
- GlycoRNAs are involved in cell-cell signaling pathways relevant to disease.
- Their aberrant expression is a hallmark of several pathological conditions.
- Targeting GlycoRNAs presents a promising, yet challenging, therapeutic avenue.
Conclusions:
- GlycoRNAs are significant biomarkers and therapeutic targets in diseases like cancer and inflammation.
- Further research is needed to overcome challenges in developing effective GlycoRNA-targeted therapies.
- Intercellular communication mediated by GlycoRNAs offers novel insights into disease mechanisms.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
08:16Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Drug Discovery: Overview
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: